Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.This is an entirely free service. No payments are to be made.
Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) contributed 29% to sales. The balance was contributed by proprietary products. In February 2006, Dr.Reddy's acquired the German company Betapharm for US$ 570 m to mark its foray into the German generics market. Company has its operation in Russai & is ranked 12th in terms of market share.
|American Depository Receipts||Apr 26, 2017|
|Price (US$)40.89||Open (US$)40.89||High (US$)54.73||Low (US$)39.04|
|% Change-2.03||Volume210,763||Value (US$)380,962||52-Week H/L68.00 / 40.67|
Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.
Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.
Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.
Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.
Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.More Views on News
Rohan and Kunal present you the discussions with professor Sanjay Bakshi in his virtual classroom.
Why HDFC Bank beat the Sensex by nearly 3 times.
An elephant and six blind men will tell you more about the markets than any financial newspaper or channel.
While it is important to get Mallya back to India, the government needs to show the same vigour in chasing defaulters of public sector bank loans residing in India.
PersonalFN explains how GST would impact India's mutual fund industry and investorsMore